Fig. 4From: MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapyReceiver operating characteristics curve analysis of radiographic progression (van der Heijde modified total Sharp score year-progression (ΔTSS) >3 versus ΔTSS ≤3, showing that serum matrix metalloproteinase-3 (MMP-3) levels of serum MMP-3 as measured at 1 year (a) or 2 years (b) after the start of methotrexate monotherapy can predict final radiographic evidence of non-progression of disease. AUC area under the curveBack to article page